A new drug combination extends by 46% the time that liver cancer remains stable, according to an international clinical trial ...
The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...
Still, Perea is not the first case of a liver transplant successfully curing bowel cancer in a patient. The body of evidence ...
Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...
This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...
New research by Oregon Health & Science University scientists has uncovered multiple factors to improve gene delivery to the ...
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Metastatic Melanoma.
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Kidney Cancer (Renal Cell Cancer).
Pathology was obtained in five cases (four RCCs and one oncocytoma). No patients died of RCC or developed metastatic disease. [24] The studies on active surveillance that have been published to ...